Fig 1.
Genomic landscape of pancreatic neuroendocrine tumors, including the first sequenced sample for each patient (n = 80), as identified by the Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets. LOH, loss of heterozygosity; Mb, megabyte; mTOR, mammalian target of rapamycin.